Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Security cameras and two barbed wire topped fences are visible at CEN Biotech's main facility in Lakeshore, Ont., Saturday, December 6, 2014.

After being refused a licence to open the world's largest medical marijuana facility, CEN Biotech is reviving its application for a judicial review.

The company was informed in February that Health Canada intended to refuse its licence, amid mounting concerns about the conduct of CEN Biotech and its chief executive officer. CEN Biotech filed for a judicial review of that decision, but withdrew its application last week.

In a press release on Thursday, the company said the original application was abandoned as a result of a "procedural issue." It said a new application would be filed by the end of next week.

Story continues below advertisement

"The dismissal is merely a procedural issue to comply with certain procedural rules of the Court," CEN Biotech said in the statement. "The Application for Judicial Review will be refiled before April 10, 2015, and will pursue the same claims and relief sought as the original filing."

Though CEN did not say what procedural issue forced the company to refile its bid for a review, such applications are usually filed after the government issues a final decision. The company filed its first bid for a judicial review in February, after Health Canada notified the company that it intended to reject the licence bid – but before the final decision came on March 11.

In its original application, CEN Biotech asked a judge to overturn Health Canada's rejection of the licence, saying that the regulator had acted unfairly.

The company applied to grow 600,000 kilograms of medical marijuana near Lakeshore, Ont., under a new federal program that began last year. However, Health Canada rejected CEN Biotech's application amid serious concerns about the company's conduct; including the emergence of multiple different signatures attributed to its CEO, Bill Chaaban, on regulatory documents; claims by CEN in business circles that it had ties to the Health Minister, which the Minister was forced to deny; and revelations that the company had fabricated the identity of an employee.

CEN's conduct came under scrutiny last year when its shares soared amid false and exaggerated statements made by the company, including claims that it had been licensed, or was close to being licensed, when it was not. The company also suggested to investors that it was partnering with Health Canada, which the government later said was misleading. Such claims helped push up the price of shares in CEN's parent company, Michigan-based Creative Edge Nutrition, by a significant amount.

At its height, the company was worth more than $350-million last year, despite having no licence to operate. At the same time those claims were being made to investors, Mr. Chaaban was selling millions of his own shares in the penny stock company at a steep profit.

The Ontario Securities Commission said last week that it has "an active investigation" into CEN Biotech and its parent firm. The regulator said it could not comment further.

Story continues below advertisement

Given that Creative Edge Nutrition is traded on the loosely regulated U.S. over-the-counter (OTC) market, it is likely that the OSC is working in conjunction with U.S. regulators on the investigation, since that is typically how it conducts such probes involving cross-border matters.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies